Fig. 2: A PERK inhibitor could inhibit the cell survival of BRAFi–resistant melanoma with impaired PTEN. | npj Precision Oncology

Fig. 2: A PERK inhibitor could inhibit the cell survival of BRAFi–resistant melanoma with impaired PTEN.

From: PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN

Fig. 2

WM88 (a) and A375sm (b) cells with wild-type PTEN or WLH6215 (c) and Sk-mel28 (d) cells with impaired PTEN and their PLX4032-resistant counterparts were treated with different concentrations of PLX4032 BRAF inhibitor (BRAFi) and GSK2606414 PERK inhibitor (PERKi). The cell viability curves of parental and resistant human melanoma cells were determined using CCK8 assays. Error bars denote s.d. for biological three repeats.

Back to article page